Lauren Buchanan, MA, Managing Editor

The FDA has released guidelines for clinicians and tips to identify the distinguishing features of counterfeit products.

Five experts delved into the latest updates to treatment guidelines and the updated label use for dupilumab for hand-foot AD.

Mona Gohara, MD, explained the importance of the products' impact on the skin barrier.

Christopher Bunick, MD, PhD, delves into current data and guidelines to consider when creating custom treatment plans for patients with atopic dermatitis.

Researchers address the persisting gaps in managing mental health comorbidities within the framework of existing clinical practice guidelines.

The submission stems from promising results from the phase 3 BE HEARD I and BE HEARD II trials.

The risk of upper respiratory infection-related mortality was notably diminished in the study's dupilumab cohort.

In this study, topical 0.1% retinol significantly improved crow’s feet, facial wrinkles, uneven skin tone, brown spots, and overall photoaging.

The new launch is set to bring berdazimer topical gel, 10.3% to adults and pediatric patients over the age of 1 with molluscum contagiosum faster.

The permanent J-code for the molluscum contagiosum treatment is now live.

Explore recent research that shed light on potential associations and manifestations post-COVID-19 infection or vaccination.

The statement said the petition came as a surprise to many ahead of AAD, and delves into the data complexity and patient considerations.

Two recent studies delve into outcomes of pediatric populations with atopic conditions and an overview of patient outcomes utilizing a Mendelian randomization analysis.

A panel of experts discusses tailoring treatment to patient needs, supporting patients' mental health, and considering future directions.

A panel of experts discusses unique needs of patients with skin of color, look at long-term safety and efficacy of emerging oral treatments, and delve into combining topicals with systemic therapies.

A panel of experts discuss navigating regimen complexity, patient-friendly adherence strategies, addressing steroid phobia and attitudes, and dive into current treatment guidelines.

Catch up on coverage from the fifth and final day of the 2024 American Academy of Dermatology Annual Meeting.

In between sessions, Lal shared his favorite pearls from AAD, a recent challenging pediatric case in his practice, the significance of LinkedIn, and more.

Arianne Shadi Kourosh, MD, MPH, FAAD, shared pearls on environmental factors that can impact skin aging and pigmentation including visible light, IR radiation, location, and pollution.

Rebecca Hartman, MD, MPH, FAAD, and Christine Kannler, MD, FAAD, took a deep dive into considerations and pearls to treat patients who have been exposed to extreme heat and chemicals in the line of duty.

Catch up on coverage from the fourth day of the 2024 American Academy of Dermatology Annual Meeting.

A vote during the annual meeting will keep DEI initiatives in place and members are awaiting news on what those initiatives will look like.

Menes Kizoulis shared key highlights from the research conducted alongside leading dermatologists, like Alan Irvine, MD, DSc, and Patricia Farris, MD, MS.

The injectable polidocanol exhibited high efficacy, quicker onset of benefit, reduced downtime, and fewer side effects lasting longer than 30 days.

Jenny Murase, MD, said the average dermatologist manages 2-3 patients with delusional infestations every 5 years. Learn what to expect and how to manage it with empathy.

Catch up on coverage from the third day of the 2024 American Academy of Dermatology Annual Meeting.

In an exclusive interview with Gary Dudzik, he shared top 5 considerations dermatology clinicians should have when choosing financial services for their practices and overall financial goals.

Lloyd Miller, MD, PhD, delves into the new data demonstrating high rates of skin clearance over 52 weeks in adults with moderate to severe plaque psoriasis.

Discover the science behind cosmeceutical advancements and the importance of staying informed for enhanced patient care with Zoe Diana Draelos, MD.

The phase 3 studies, BE HEARD I and BE HEARD II, showed significant improvements in skin pain over the 48-week period.